Aris Angelis: The use of the ESMO MCBS for coverage and reimbursement decisions of cancer medicines
“In 2019, in collaboration with ESMO – European Society for Medical Oncology, we came up with a proposal for the development of a value framework for the reimbursement of new cancer medicines.
In 2021, we drafted a paper on the use of the ESMO Magnitude of Clinical Benefit Scale (MCBS) for coverage and reimbursement decisions of cancer medicines as a retrospective study on HTA outcomes and their timelines.
In 2024, just before the end of the year, the paper has finally been published in The Lancet Group Oncology! Many thanks to Panos Kanavos and Erica Visintin for pushing the initiative forward until the very end!
Data were extracted from publicly available HTA reports and related sources from six country settings and their respective HTA agencies (Australia, Canada, England, France, the Canadian province of Quebec, and Scotland).
We evaluated new cancer medicines for treating solid tumors in a non-curative setting with published ESMO-MCBS scores and that had been assessed by at least three HTA agencies between Jan 1, 2011, and Dec 31, 2020.
Using the ESMO-MCBS score as an independent variable, we did descriptive and multivariable regression analyses to evaluate: (1) factors associated with the time between marketing authorisation and positive HTA outcome; and (2) factors associated with HTA outcomes.
Several factors informed HTA outcomes for new cancer medicines. A high ESMO-MCBS score, defined as indicating substantial clinical benefit, increased the likelihood of a positive HTA outcome and shortened the interval between marketing authorisation and HTA outcome, and this association was not affected by other variables.
Additional factors informing HTA outcomes include evidence uncertainties and unmet medical needs. Country-relevant differences exist in the time-to-HTA outcome and the propensity of some countries to achieve positive (restricted or unrestricted) outcomes compared with others.”
Authors: Panos Kanavos, Erica Visintin,
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023